Ming Jiang

Title: **Ming Jiang: Innovator in Blood-Clotting Factor VIII Technology**

Introduction

Ming Jiang, an accomplished inventor based in Kaifeng, China, is recognized for his significant contributions to biotechnology. With a focus on enhancing therapeutic proteins, he has developed innovative solutions that address critical medical challenges. Jiang's work primarily revolves around the enhancement of blood-clotting factors, which are vital for patients with bleeding disorders.

Latest Patents

Jiang holds a notable patent titled "Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same." This invention involves a highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein designed to improve pharmacokinetics and drug efficacy. The fusion protein incorporates a flexible peptide connector, a rigid unit from a human chorionic gonadotropin β-subunit, and a half-life extending portion selected from a human IgG Fc variant. Remarkably, it achieves a similar level of biological activity to recombinant FVIII while extending its in vivo half-life.

Career Highlights

Throughout his career, Ming Jiang has demonstrated expertise in protein engineering and biotechnology. He has been affiliated with prominent companies, including Ampsource Biopharma Shanghai Inc. and Furen Pharmaceutical Group Co., Ltd. These experiences have provided him with a platform to advance his research in therapeutic proteins and their applications in medicine.

Collaborations

Jiang has collaborated with notable coworkers such as Qiang Li and Wenchen Zhu. These partnerships have enabled him to leverage shared expertise and resources, ultimately enriching his research endeavors and leading to successful innovations in his field.

Conclusion

Ming Jiang stands out as a key figure in the development of blood-clotting therapies. His patent on the glycosylated FVIII fusion protein marks a significant advancement in the treatment of bleeding disorders, showcasing his innovative spirit and commitment to improving patient outcomes. Jiang's work reflects the potential of biotechnology to transform healthcare and enhance the quality of life for individuals with clotting deficiencies.